Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. Ocular myasthenia gravis in a person with tetraplegia presenting challenges in diagnosis and management

Ocular myasthenia gravis in a person with tetraplegia presenting challenges in diagnosis and management

Spinal Cord Series and Cases, 2016 · DOI: 10.1038/scsandc.2015.37 · Published: April 7, 2016

Spinal Cord InjuryNeurologyResearch Methodology & Design

Simple Explanation

This case report describes a man with tetraplegia who developed ocular myasthenia gravis (OMG). The OMG diagnosis was complicated by his existing conditions and medications. Managing his OMG symptoms created new problems with bladder control and blood pressure. The patient's OMG was treated with pyridostigmine, which helped his eye symptoms but worsened his abdominal spasms and autonomic dysreflexia. Doctors had to stop the pyridostigmine and find another way to manage his double vision. Ultimately, the patient's OMG was managed with an eye patch to alleviate double vision. He continued to have health problems and died five months later from a heart attack.

Study Duration
5 months
Participants
A 61-year-old man with C5 AIS A tetraplegia
Evidence Level
Level 4; Case Report

Key Findings

  • 1
    The patient's ocular signs responded well to pyridostigmine.
  • 2
    Unopposed anti-cholinesterase activity led to frequent and painful abdominal spasms, associated with uncontrolled detrusor hyperreflexia and worsening autonomic dysreflexia (AD).
  • 3
    Diagnostic difficulties may arise where the pattern of weakness mimics impairment of either third, fourth or sixth cranial nerve function, unilaterally or bilaterally.

Research Summary

This case report describes a 61-year-old man with tetraplegia who developed ocular myasthenia gravis (OMG), presenting diagnostic and management challenges due to pre-existing conditions and conflicting medication effects. The patient's treatment with pyridostigmine for OMG exacerbated abdominal spasms and autonomic dysreflexia, necessitating discontinuation and alternative management with an eye patch. The case highlights the difficulties in balancing MG treatment with management of SCI-related impairments and emphasizes the importance of considering complex comorbidities in patients with tetraplegia.

Practical Implications

Diagnostic Awareness

Clinicians should consider OMG in patients with tetraplegia presenting with new ocular symptoms, even if typical patterns are masked.

Treatment Balancing

Careful consideration of drug interactions and side effects is crucial when treating OMG in patients with SCI due to potential conflicts with existing medications.

Multidisciplinary Approach

Managing OMG in tetraplegic patients requires a collaborative approach involving neurologists, spinal cord injury specialists, and other healthcare professionals.

Study Limitations

  • 1
    Single case report limits generalizability.
  • 2
    Negative acetylcholine receptor antibodies may have delayed diagnosis.
  • 3
    Patient's multiple comorbidities complicated the management and interpretation of treatment effects.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury